Клиническая онкогематология

Клиническая онкогематология

Фундаментальные исследования и клиническая практика

Menu

  • Home
  • About
    • Aims and Scope
    • Editorial board
    • Indexing and Abstracting
    • Peer Review
    • Publishing Ethics and Malpractice Statement
    • Open Access Policy and Publication Fee
  • Archive
    • 2023
      • № 1/2023
    • 2022
      • № 1/2022
      • № 2/2022
      • № 3/2022
      • № 4/2022
    • 2021
      • № 1/2021
      • № 2/2021
      • № 3/2021
      • № 4/2021
    • 2020
      • Issue 1/2020
      • Issue 2/2020
      • Issue 3/2020
      • Issue 4/2020
    • 2019
      • №1/2019
      • № 2/2019
      • № 3/2019
      • № 4/2019
    • 2018
      • №1/2018
      • №2/2018
      • №3/2018
      • №4/2018
    • 2017
      • №1/2017
      • №2/2017
      • №3/2017
      • №4/2017
    • 2016
      • №1/2016
      • №2/2016
      • №3/2016
      • №4/2016
    • 2015
      • №1/2015
      • №2/2015
      • №3/2015
      • №4/2015
    • 2014
      • № 1/2014
      • №2/2014
      • №3/2014
      • №4/2014
    • 2013
      • №1/2013
      • №2/2013
      • №3/2013
      • №4/2013
  • Submission
    • Submit manuscript

Low-Risk Myelodysplastic Syndromes

AUTOIMMUNE THROMBOCYTOPENIA

SV Gritsaev

Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024

For correspondence: Sergei Vasilevich Gritsaev, MD, PhD, Head of Republican Center for Bone Marrow Transplantation, Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024; e-mail: gritsaevsv@mail.ru

Interview conducted by Prof. E.A. Osmanov, MD, PhD.


Read in PDF

  • ← Acute Myeloid Leukemia Patient-Derived Xenograft Models Generated with the Use of Immunodeficient NSG-SGM3 Mice
  • Treatment Opportunities in Relapsed Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphomas (Resolution of Expert Panel) →

Languages

  • ru 
  • en 
  • Supportive Therapy in Multiple Myeloma: Practical Recommendations
  • Primary Immune Thrombocytopenia and Thrombopoietin Receptor Agonists: Feasibilities of Treatment Discontinuation upon Achieving Stable Complete Platelet Response
  • Cardiovascular Complications of the Immunotherapy of Hematological Malignancies: A Literature Review
  • An Optimal Multi-Locus HLA-Typing in Potential Donors of Allogeneic Hematopoietic Stem Cells
  • BAALC-Expressing Leukemia Hematopoietic Stem Cells and Their Place in the Study of CBF-Positive Acute Myeloid Leukemias in Children and Adults